iRadimed (NASDAQ:IRMD) CEO Sells $462,600.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $92.52, for a total transaction of $462,600.00. Following the completion of the transaction, the chief executive officer owned 2,212,500 shares in the company, valued at $204,700,500. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Down 0.8%

IRMD traded down $0.76 during trading on Wednesday, hitting $92.80. The company’s stock had a trading volume of 34,452 shares, compared to its average volume of 80,043. iRadimed Corporation has a one year low of $50.00 and a one year high of $107.90. The firm has a market cap of $1.19 billion, a PE ratio of 53.03 and a beta of 1.11. The business’s 50 day simple moving average is $99.13 and its 200-day simple moving average is $92.76.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The business had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities research analysts expect that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a $0.20 dividend. The ex-dividend date was Monday, February 23rd. This is a boost from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is 45.71%.

Institutional Trading of iRadimed

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock valued at $1,354,000 after acquiring an additional 3,307 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after buying an additional 234 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of iRadimed by 8,568.5% in the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after buying an additional 11,139 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of iRadimed by 1.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after buying an additional 1,821 shares in the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, iRadimed has a consensus rating of “Buy” and a consensus price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.